氯吡格雷对冠状动脉介入治疗后血清sCD40L及sICAM-1的影响  

Effect of clopidogrel on serum sCD40L and sICAM-1 of patients after coronary intervention

作　　者：朱磊 李春坚[2] 

机构地区：[1]襄阳市第一人民医院心血管内科,湖北襄阳441000 [2]南京医科大学第一附属医院,南京210000

出　　处：《实用药物与临床》2016年第6期674-676,共3页Practical Pharmacy and Clinical Remedies

基　　金：国家自然科学基金(81170181)

摘　　要：目的探讨氯吡格雷对冠心病患者冠脉内介入治疗(PCI)疗效的影响。方法选取2012年5月至2014年10月我院收治的冠心病患者45例作为研究组,另取造影正常的45例患者作为对照组,所有患者均接受抗心绞痛治疗,在PCI治疗前给予研究组患者氯吡格雷75 mg/d,使用酶联免疫吸附法(ELISA)检测术前1d、术后1 d和术后5 d患者血清中s CD40L和s ICAM-1的浓度,比较两组之间的差异。结果术前1 d、术后1 d研究组患者血清中s CD40L和s ICAM-1浓度水平明显低于对照组,差异有统计学意义(P<0.05),术后5 d两组s CD40L和s ICAM-1水平比较差异无统计学意义(P>0.05);对照组患者血清中s CD40L和s ICAM-1浓度水平基本维持不变,而研究组患者血清中s CD40L和s ICAM-1浓度水平逐渐降低。结论氯吡格雷可降低冠心病患者PCI术后早期血清s CD40L和s ICAM-1浓度水平,有效预防血栓发生。Objective To explore the role of clopidogrel in the percutaneous coronary intervention（PCI）therapy.Methods Forty-five cases of coronary heart disease patients in our hospital who accepted anti-anginal therapy were included as study group another 45 angio graphically normal patients as control group.Patients in study group were treated with 75 mg/d clopidogrel before PCI.ELISA was applied to detect the concentration of sCD40 L and sICAM-1at 1 d before PCI and 1 and 5 d after PCI,and the difference between the two groups was compared.Results The concentration of sCD40 L and sICAM-1 at 1 d before PCI 24 h after PCI in study group were significantly lower than that of control group（P〈0.05）,while the difference of sCD40 L and sICAM-1 levels between the two groups was not statistically significant（P〉 0.05） at 5 d after PCI.The sCD40 L and sICAM-1 levels remain almost the same in control group while their concentration decreased in study group.Conclusion Clopidogrel can reduce the concentration of sCD40 L and sICAM-1 after PCI in the patients with coronary heart disease,thus preventing the occurrence of thrombo—embolic events.

关 键 词：冠心病 氯吡格雷 PCI SICAM-1 s CD40L 

分 类 号：R541.4[医药卫生—心血管疾病]